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Calcium nephrolithiasis is one of the most prevalent
uronephrologic disorders in the western countries. Studies
in families and twins evidenced a genetic predisposition to
calcium nephrolithiasis. Family-based or case–control studies
of single-candidate genes evidenced the possible
involvement of calcium-sensing receptor (CASR), vitamin D
receptor (VDR), and osteopontin (OPN) gene polymorphisms
in stone formation. The only high-throughput genome-wide
association study identified claudin 14 (CLDN14) gene as a
possible major gene of nephrolithiasis. Specific phenotypes
were related with these genes: CASR gene in normocitraturic
patients, VDR gene in hypocitraturic patients with severe
clinical course, and CLDN14 gene in hypercalciuric patients.
The pathogenetic weight of these genes remains unclear,
but an alteration of their expression may occur in stone
formers. Technological skills, accurate clinical examination,
and a detailed phenotype description are the basis to get
new insight about the genetic basis of nephrolithiasis.
Kidney International (2011) 80, 587–593; doi:10.1038/ki.2010.430;
published online 20 October 2010
KEYWORDS: calcium-sensing receptor; calciuria; citraturia; gene expression;
kidney stones
Calcium nephrolithiasis is one of the most prevalent
uronephrologic disorders in western countries. It is a hetero-
geneous disease because of the multiple factors promoting or
inhibiting calcium salt precipitation in the urinary environ-
ment. Genetic analysis may identify individuals predisposed
to calcium stones, but also contribute to understand
mechanisms of stone formation and to predict the response
to drugs and nutrients. Single-candidate gene polymorph-
isms have been mainly explored in stone formers, however, it
is likely that in the near future genotyping of the whole
genome will enable us to characterize single individuals
according to their genetic profile of stone risk, appropriate
therapy, and diet with sufficient scientific evidence.
Family and twin studies evidenced the importance of
genes in calcium nephrolithiasis. The prevalence of stone
formers was higher among the relatives of stone-forming
patients than the relatives of the healthy individuals in
different western countries.1,2 A greater concordance of stone
production was observed among monozygous than dizygous
twins born in Vietnam.3 Heritability of calcium nephro-
lithiasis (Table 1) was calculated around 50% in these studies.
Family studies also disclosed that stone transmission pattern
was not mendelian, but consistent with a complex polygenic
substrate that may be heterogeneous in different patient
groups.1,2 Major genes were hypothesized,4 but an alternative
pattern with multiple genes exerting small and additive
effects on stone susceptibility was considered by other
researchers.1,2,5
In spite of the social impact of nephrolithiasis and the
clinical relevance of genetic research, few studies have
searched genes of calcium nephrolithiasis in comparison
with other complex diseases. In the period 2008–2009, only
one paper studied calcium nephrolithiasis with the modern
strategy of the genome-wide association study (GWAS),
whereas B21 papers did it in diabetes mellitus, 12 papers
in hypertension, and 9 papers in osteoporosis. These
observations underline the poor attention dedicated to
nephrolithiasis by public and private sources of funding
and even by researchers themselves.
NEPHROLITHIASIS IN MONOGENIC DISORDERS
Rare monogenic diseases with mendelian transmission
pattern may present calcium stones in their clinical picture
(Table 2).6–16 Common nephrolithiasis is not explained
by these genes, even though mutations at chloride channel
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5 (CLCN5) and phosphate carrier (SLC34A3) genes, causing
Dent’s disease, and hereditary hypophosphatemic rickets with
hypercalciuria, respectively, may justify sporadic cases in
patients without any other defects typical of these two
disorders.7,14 Polymorphisms of these genes could contribute
to increase the individual susceptibility to calcium stones, but
Table 2 | Hereditary diseases causing nephrolithiasis and/or nephrocalcinosis
Gene
Locus/
inheritance
mode Protein Cellular defect Tubular defect Disorder Ref.
CLCN5 Xp11.22
X-linked
recessive
Chloride channel 5
on the endosome
membrane
Impaired acidification of the
endosome fluid in proximal
tubular cells.
Multiple reabsorption defects
in the proximal tubule. Stones,
nephrocalcinosis and possible
end-stage renal failure.
Dent’s syndrome Cho et al.6 and
Scheinman et al.7
OCRL1 Xq26.1
X-linked
recessive
Phosphatidylinositol
4,5-bisphosphate
5-phosphatase
Accumulation of
phosphatidylinositol 4,5-
bisphosphate in proximal cells,
followed by actin
polymerization, and tight and
aderens junction defects.
Multiple reabsorption defects
in the proximal tubule. Stones,
nephrocalcinosis and possible end-
stage renal failure. Hydrophthalmia,
cataract, mental retardation.
Dent’s syndrome 2
Lowe syndrome
Cho et al.6
CLDN16 3q27
Autosomal
dominant
Claudin 16 Alteration of tight junction ion
selectivity in the thick ascending
limb of Henle loop.
Urinary loss of magnesium and
calcium, nephrocalcinosis, and
progressive kidney failure in
homozygotes. Heterozygotes may
produce kidney stones.
Familial
hypomagnesemia with
hypercalciuria and
nephrocalcinosis
Muller et al.8
CLDN19 1p34.2
Autosomal
dominant
Claudin 19 Alteration of tight junction ion
selectivity in the thick ascending
limb of Henle loop.
Renal wasting of magnesium and
calcium, nephrocalcinosis and
progressive kidney failure
in homozygotes. Macular
colobomata, myopia, and
nystagmus.
Familial
hypomagnesemia with
hypercalciuria and
nephrocalcinosis with
ocular impairment
Konrad et al.9
ATP6N1B 7q33-q34
Autosomal
recessive
b-Subunit ATP6N1B
of the H-pump
Defect of the proton secretion
and urine acidification in the
a-intercalated cells of the
collecting duct.
Hypokalemic hyperchloremic
acidosis with nephrocalcinosis and
kidney stones.
Distal tubular acidosis Smith et al.10
ATP6B1 2cen-q13
Autosomal
recessive
Subunit ATP6B1 of
the H-pump
Defect of the proton secretion
and urine acidification in the
a-intercalated cells of the
collecting duct.
Hypokalemic hyperchloremic
acidosis with nephrocalcinosis and
kidney stones. Neural deafness.
Distal tubular acidosis
with progressive neural
deafness
Karet et al.11
SLC4A1 17q21-q22
Autosomal
dominant
Anion exchanger Decreased bicarbonate
reabsorption at the basolateral
membrane of the a-intercalated
cells of the collecting duct.
Hypokalemic hyperchloremic
acidosis, nephrocalcinosis and
kidney stones. Kidney stones and
incomplete tubular acidosis in
heterozygotes.
Distal tubular acidosis Bruce et al.12
SLC34A3 9q34
Autosomal
recessive
NPT2c sodium-
phosphate
cotransporter
Reduced phosphate
reabsorption and increased
calcitriol synthesis in the
proximal tubular cells.
Severe rickets and kidney stones
caused by renal loss of phosphate,
hypophosphatemia, and
hypercalciuria.
Hypophosphatemic
rickets with
hypercalciuria
Bergwitz et al.13
and Tencza et al.14
CASR 3q13.3-q21
Autosomal
dominant
Calcium-sensing
receptor (activating
mutations)
Inhibition of calcium
reabsorption in the ascending
limb of Henle loop.
Hypercalciuria and hypocalcemia.
Hyperphosphatemia and
hypophosphaturia. Renal
hypopotassemia if very potent effect
of the mutation.
Autosomal-dominant
hypoparathyroidism
Bartter syndrome type 5
Pearce et al.15
SLC12A1 15q15-q21.1
Autosomal
recessive
NKCC2 sodium-
potassium-chloride
transporter
Decreased sodium, potassium
and chloride reabsorption in the
ascending limb of Henle loop.
Renal hypokalemia, alkalosis,
hypercalciuria, secondary
aldosteronism and nephrocalcinosis.
Bartter syndrome type 1 Puricelli et al.16
KCNJ1 11q24
Autosomal
recessive
ROMK1 potassium
channel
Decreased sodium, potassium
and chloride reabsorption in the
ascending limb of Henle loop.
Renal hypokalemia, alkalosis,
hypercalciuria, secondary
aldosteronism and nephrocalcinosis.
Bartter syndrome type 2 Puricelli et al.16
Gene mutations cause phenotypic alterations at protein, cellular, and body level that are described in the table. All these mutations cause a protein loss-of-function with the
exception of CASR gene mutations that cause nephrolithiasis in the presence of activating mutations.
Table 1 | Glossary
Epigenetic/epigenomic: they define the molecular mechanisms that influence the phenotypic outcome of a gene/genome in absence of changes to the
underlying DNA sequence. It may be mediated by methylation or other covalent modifications of chromatin or other forms of chromatin reorganization
that are important for the control of gene transcription. Epigenetic change may be inherited in somatic cells.
Haplotype: a combination of genetic polymorphisms that are inherited together.
Heritability: the proportion of the phenotypic variation explained by genes.
Metabolomics: the study of the comprehensive analysis of all metabolites (metabolome) in a tissue, biological fluid, or cell under a given set of
conditions.
Nutrigenetics/nutrigenomics: the study of the interaction between nutrients and an individual’s genetic/genomic polymorphisms.
Proteomics: the large-scale study of proteins (proteome) in a tissue, biological fluid, or cell under a given set of conditions.
Transcriptomics: the study of the complete set of RNA transcripts (transcriptome) produced by the genome under a given set of conditions.
Transcription factor: a protein that binds to the regulatory region of a gene regulating its transcription.
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only the calcium-sensing receptor (CASR) gene was screened
in idiopathic stone formers.
GENETIC APPROACH TO THE HUMAN IDIOPATHIC CALCIUM
NEPHROLITHIASIS
The first approach of genetic research to nephrolithiasis was
to test candidate genes, selected according to the current
pathogenetic theories, by family-based linkage disequilibrium
or association analysis in cases and controls. Linkage
disequilibrium analysis tests the segregation of a trait with
genetic markers, usually polymorphisms or simple sequence
repeats. It is reliable to identify quantitative trait loci of
monogenic disorders, but it is unable to identify loci with a
small determination power on the phenotype of interest.17
Furthermore, it may be difficult to find large families on
multiple generations, or a large number of nuclear families
for linkage disequilibrium analyses. Therefore, researchers
have more often used the alternative approach of association
studies comparing allele distribution in cases and controls.
This method may disclose genes with a small effect on stone
susceptibility, but are exposed to the risk to claim falsely true
an association because of an unknown stratification or
relatedness or genetic heterogeneity or misclassification in
cases and controls.18 In addition, the phenotypic effect of a
gene may depend on its interaction with the environment or
other genes (epistasis) and may be different in relation with
the context where it is exerted.18,19 These considerations
explain why findings of association studies were often not
replicated in different populations, but also suggest that these
studies need large samples to group patients according to
their phenotype and genetic background and to avoid being
underpowered.
Candidate genes in calcium nephrolithiasis have been
mainly selected for the role of their products in calcium
metabolism or calcium salt precipitation. Linkage disequi-
librium with the loci of the 1a-hydroxylase of the 25(OH)-
hydroxyvitamin D (VDD1), vitamin D receptor (VDR),
CASR, uromodulin (UMOD), osteocalcin (OCG), and
osteopontin (OPN) was examined in a large cohort of
French–Canadian sib-pairs concordant for stones.20–23 Of
these candidates, only VDR locus (12.q12-14) showed linkage
with nephrolithiasis. It was mapped with six microsatellite
markers or intragenic restriction fragment length poly-
morphisms. Four of the six markers were positive for
linkage with stones and one with calcium excretion.21 These
findings were confirmed in six Indian families, but not in
nine European families with hypercalciuric stone-forming
members.24,25
ASSOCIATION STUDIES OF SINGLE-CANDIDATE GENES
Case–control studies observed an association of nephrolithia-
sis with the VDR gene polymorphisms at the 30-untranslated
end region, characterized by restriction fragment length
polymorphisms analysis with BsmI, ApaI, TaqI enzymes (the
first two sited on the intron 8 and the third on the exon 9, but
synonymous) and the translation starting codon, characteri-
zed by restriction fragment length polymorphisms analysis
with FokI enzyme.26,27 Variant alleles at both sites also
correlated to the severity of stone disease, being associated
with early age of onset, higher frequency of stones and lower
urinary citrate excretion.26,28 The in vitro functional study of
the 30-untranslated end region polymorphisms indicates that
the polymorphic alleles associated to stones decrease VDR
expression by modifying VDR mRNA stability or transcrip-
tion.29 As VDR may inhibit the transcription of the
phosphoenolpyruvate carboxykinase that stimulates citrate
reabsorption in proximal tubular cells, it was hypothesized
that less active VDR variants explain the severity of stone
disease through an increased citrate reabsorption.30
CASR is a membrane protein expressed throughout the
kidney tubule and sensitive to extracellular calcium. The
increase of interstitial calcium stimulates CASR to inhibit
calcium reabsorption in the ascending limb while its increase
in tubular fluid of the collecting duct inhibits the vasopressin
effect on water reabsorption and enhances proton secretion
(Figure 1). CASR also improves phosphate reabsorption
antagonizing parathyroid hormone phosphaturic activity in
the proximal tubule.31 CASR gene (3q13.3-21) was associated
with idiopathic calcium stones in two studies, despite a
negative linkage disequilibrium analysis.22 The first
one genotyped 223 Canadian stone formers for R990G
polymorphism and observed an increased risk of stones in
homozygous individuals for the 990G variant allele.32 R990G
AQP2
CASR
H-pump
AQP2
H2O
HPO4
H3PO4
H
ADP
ATP
Ca
Ca
–
+
Lumen Interstitium
Figure 1 |When the concentration of calcium increases in the
tubular fluid, two counterbalancing mechanisms are
activated by the calcium-sensing receptor (CASR) in the distal
tubule. Here, CASR stimulates proton excretion by H-pump in
intercalated cells and decreases water reabsorption by the
reduction of aquaporin 2 (AQP2) expression on the apical
membrane. As a consequence, urine dilution and acidification
protect against calcium-phosphate salt precipitation within the
tubular lumen. It is noteworthy that CASR is not a regulator of
urine pH or osmolality, but may have a local effect on tubular
handling of protons and water. ADP, adenosine diphosphate; ATP,
adenosine triphosphate.
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was also associated with primary hypercalciuria and an
in vitro test showed that its 990G allele produced a gain of the
CASR function.33 Its association with nephrolithiasis was
replicated in Italian patients with primary hyperparathyroid-
ism.34 The other study found that variant alleles at two
polymorphisms located on the 50-untranslated end region
and the first intron of the CASR gene and a haplotype
including them were more frequent in 312 normocitraturic
kidney stone formers than 213 controls.35 The association of
these polymorphisms with nephrolithiasis was also observed
in primary hyperparathyroidism comparing stone-forming
and stone-free patients.36 Both polymorphisms were in the
first haplotype block of the CASR gene also including gene
promoters. Polymorphisms at this region could change
promoter activity or transcription factors-binding sites,
resulting in the modification of the CASR expression.36 No
in vitro studies have functionally characterized these poly-
morphisms so far, but clinical findings in idiopathic and
hyperparathyroid stone formers suggest that the CASR
expression may decrease in presence of their variant alleles.
Decreased CASR expression in kidney could predispose to the
intratubular calcium phosphate precipitation and calcium
phosphate stone formation (Figure 2) by increasing phos-
phate release to the distal tubule and decreasing preurine
acidification and dilution capability.31 A decreased CASR
expression could predispose to calcium oxalate stones if it
favors hydroxyapatite deposition in the papillary interstitium
as Randall’s plaque.37 A protective CASR activity against
hydroxyapatite precipitation in soft tissues was observed in
artery walls.38
OPN is a urinary crystallization inhibitor. Despite negative
linkage analysis,23 three studies observed that OPN gene
(4q21.1-25) polymorphisms were diversely distributed in
stone formers and controls. OPN gene was mapped with
23 polymorphisms in 126 Japanese patients. Polymorphisms
sited within gene promoter at 144 and 145 locations were
associated with calcium stones without relationships with
intermediate phenotypes.39 Another polymorphism at loca-
tion 156 in the OPN gene promoter was associated with
calcium stones in 249 patients from Taiwan.40
Association of nephrolithiasis with polymorphisms of the
TRPV6, matrix-gla protein, urokinase, interleukin 1 receptor,
interleukin 18, epidermal growth factor, and E-cadherin genes
were also observed, but have not been replicated in other
studies.41–47
GWASs IN NEPHROLITHIASIS
Three association studies mapped the whole genomic DNA
with polymorphic markers to find loci associated or in
linkage disequilibrium with nephrolithiasis but only one of
them was carried out with a modern high-throughput
platform able to test thousands of markers in thousands of
subjects. The strategy of these studies avoids candidate-genes
and allows to identify otherwise unpredictable loci involved
in calcium nephrolithiasis. GWASs represent a fundamental
advance for genetic research, but require specific bioinfor-
matic software for data analysis and a large number of
patients to keep their statistical power.48 Despite their
importance, GWAS findings often explain a small proportion
of the causes of the complex non-mendelian diseases.48
The first study mapped total DNA using 380 polymorphic
microsatellite markers in 18 members (10 stone formers) of a
Spanish family and identified a quantitative trait loci at
the chromosome 9q33.2-34.2 by linkage disequilibrium
analysis.49 The authors proposed no genes to explain
nephrolithiasis, although SLC34A3 gene (coding for the
NPT2c proximal sodium-phosphate carrier) is located at this
locus13 and its polymorphisms could account for the low
serum concentrations of phosphate and hypercalciuria often
detected in stone patients.50
The second study considered stone forming patients with
primary hypercalciuria from three families and found a
quantitative trait loci at the 1q23.3-24 locus by linkage
analysis with multiple markers mapping the whole genome
at low-density.51 The subsequent association analysis of
candidate-genes at this locus with multiple markers in cases
and controls recognized that minor alleles at six polymorph-
isms of bicarbonate-sensitive adenylate cyclase gene (sAC)
were more common in stone formers than controls. sAC is
expressed in kidney, intestine, and bone cells and its activity
is modulated by bicarbonate ions and divalent cations,52 but
its role in hypercalciuria and stone production remains
Randall’s
 plaque 
Kidney 
papilla 
Bellini
duct 
Apatite
nodule
Ca-phosphate
stone 
Ca-oxalate
stone 
Figure 2 | Two different pathogeneses have been hypothesized
for calcium-phosphate and calcium-oxalate stones. Both
hypotheses suggest that stone formation occurs on the papilla
surface. Calcium-phosphate stones may form as a consequence of
the accumulation of calcium-phosphate precipitates at the tip of
the Bellini duct (in the right part of the figure). Calcium-oxalate
stones may be caused by the precipitation of calcium-oxalate on
the Randall’s plaque when the papillary urothelium ulcerates and
the Randall’s plaque is wet by urine (left part of the figure).
Randall’s plaque is made of hydroxyapatite and is sited in the
papillary interstitium. Its formation may start from the basal
membrane of the tubular cells of the descending limb of Henle
loop.37 Cellular activity could be necessary in Randall’s plaque
formation.
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controversial. Another study found no linkage with
1q23.3-24 locus in nine European hypercalciuric families
(not necessarily with stones), although it used the same
markers of the previous works.53
The most recent GWAS used a high-throughput screening
technology to examine the whole genomic DNA with
thousands of markers in 3773 patients with radiopaque
stones and 42510 controls from Iceland and The Netherlands.
These individuals were genotyped for 303120 polymorphic
markers selected from International HapMap project.
Variants at four claudin 14 gene polymorphisms (CLDN14,
21q22.3) were associated with nephrolithiasis. Patients
carrying minor alleles at these polymorphisms had higher
calcium excretion and lower total plasma CO2. CLDN14 is a
member of claudin family expressed in the cellular tight
junction of the distal tubule. Two polymorphisms were sited
2020 bases apart on either sides of the last exon of the
CLDN14 gene, whereas the other two polymorphisms were
synonymous.54 The authors hypothesized that these poly-
morphisms may influence mRNA stability or processing or
be in linkage with undefined loci regulating CLDN14
expression. Another component of the claudin family,
CLDN16, has been involved in sporadic forms of calcium
stones, because their mutations cause familial hypomagne-
semia with hypercalciuria and nephrocalcinosis.55 Claudins
are transmembrane proteins and important components of
the tight junctions where they are connected with ZO-1
protein and actin of the cytoskeleton to regulate the
paracellular permeability to water and ions and preserve cell
polarity. The role of claudins and tight junctions for the stone
production is as yet unclear (Figure 3).
REMARKS ABOUT FINDINGS OF THE GENETIC RESEARCH
IN NEPHROLITHIASIS
Findings of the genetic studies indicate that CLDN14, CASR,
OPN, and VDR genes may be implicated in human calcium
nephrolithiasis. The pathogenetic weight of these genes
remains unclear, but the characteristics of the tested
polymorphisms suggest that the expression of these genes is
modified in stone formers.
CLDN14 gene was identified by a GWAS as a possible
major gene of nephrolithiasis in populations from Iceland
and The Netherlands,54 although other major genes might act
in other populations or specific patient subgroups. The fact
that only one gene was identified with a GWAS (although it
also depends on the level of the statistical significance)
suggests that calcium nephrolithiasis has features that make
more difficult to recognize its causal genes in comparison
with other complex disorders, like osteoporosis, hyperten-
sion, or diabetes, where GWASs detected multiple associated
loci.48 It also indicates that major genes may not be necessary
to explain stones formation that may instead result from the
additive effects of many predisposing genes. Each additive
gene is unable to cause stones by itself, because of its small
effect size, and only the sum of the phenotypic effects
of multiple genes can rise individual susceptibility above the
threshold of stone formation. The gene detection power of
GWASs may also be paradoxically limited by the great
number of needed patients that does not distinguish specific
subgroups of patients with homogeneous phenotype and
different genetic causes including rare variant alleles.48
Therefore, the candidate-gene approach might still be useful
to analyze patients with a well-characterized phenotype,
especially when their involvement is supported by functional
studies in animals or cultured cells.
Polymorphisms at CASR, VDR, and CLDN14 genes were
associated with stones in presence of specific phenotypes:
CASR gene polymorphisms in normocitraturic patients,
VDR gene polymorphisms in hypocitraturic patients with a
severe clinical course, and CLDN14 gene polymorphisms in
hypercalciuric patients. A strategy grouping stone formers
according to their intermediate phenotypes may be recom-
mended to distinguish the patients having the same causing
genes. An appropriate description of the patients is therefore
necessary and should include social, cultural, nutritional,
clinical, and also molecular information. Thanks to techno-
logical advances of transcriptomics, proteomics and meta-
bolomics (Table 1), methods are now available to analyze the
CASR
CLDN16
+8 mV
Lumen Interstitium
K+
2CI+
Na+
K+
0 mV 
–
–
Mg 
Ca 
ROMK
NCCT
Tight junction
Figure 3 |Claudins are transmembrane proteins and
important components of the tight junctions where they are
connected with ZO-1 protein and actin of the cytoskeleton to
regulate the paracellular permeability to water and ions and
preserve cell polarity. Claudin 16 (CLDN16) is detected in cells of
the ascending limb. Its variants may change tight junction
permeability and paracellular reabsorption of divalent cations
driven by the electric gradient maintained by potassium-
channel (ROMK) and sodium-chloride cotransport (NCCT). The
calcium-sensing receptor (CASR) inhibits the expression of claudin
16 in tight junctions and the activity of NCCT, thus decreasing the
paracellular reabsorption of calcium and magnesium. Claudin
14 is located in cells of the distal convoluted tubule and its role
is as yet unclear.
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whole mass of products in biological fluids and tissues and
may be applied to characterize stone former phenotype at
the molecular level. Their findings may be combined with
those of GWAS in a modern and systemic approach to
complex diseases, such as calcium nephrolithiasis. At present,
transcriptomic analysis has been performed only in tissue
samples from stone forming rats and evidenced that most
of involved genes were mapped on rat chromosome 1 and
their products influenced calcium handling.56 On the
contrary, proteomics, and metabolomics have not been so
far experimented in nephrolithiasis. Accordingly, if the OPN,
CLDN14, CASR, and VDR gene polymorphisms modify gene
expression, the study of their transcripts or proteins in the
kidney might be important to understand the functional
consequences of their genetic variants, although multiple
genetic and environmental components may contribute to
modify gene transcription and mRNA processing.
TOWARD THE GENETIC PROFILING OF STONE FORMERS?
Probably, the hope of many researchers is to trace the
individual genetic profile useful to define the calcium stone
risk, the response to treatment and the most preventive
lifestyle. The modern high-throughput technology may
provide the information useful to fulfill this hope. However,
genes explain around 50% of the predisposing factors to
stones and the weight of a gene in lithogenesis may change
as a function of the genetic and environmental context.1–3 On
the other side, environment and diet explain the residual
predisposition to stones and may modify gene expression at
different biological levels. They may influence the phenotypic
effects of gene products, but also modify gene transcription
and expression. Great importance has been recently attrib-
uted to the epigenetic control of gene transcription that
occurs by gene methylation or other covalent modifications
induced by environmental factors and programmed during
the early postnatal and fetal life (in this case maternal diet
and lifestyle). Epigenetic programming may be inherited
and may be involved in predisposition to complex diseases.57
This view provides a new light to the possible role of
environment and diet in calcium nephrolithiasis. It may be a
promising issue for future studies of nutrigenetics or
nutrigenomics exploring nutrient effect on the association
between genotypes and stones.
CONCLUSIONS
CLDN14, CASR, OPN, and VDR genes have been implicated
in susceptibility to calcium nephrolithiasis. Other genes may
likely be involved and the technological and bioinformatic
advances are improving our possibility to understand them.
However, genetic susceptibility to stones has to be defined
in relation to the individual environmental and genetic
context. Therefore, modern genetic studies need a very large
number of individuals having, as much as possible, homo-
geneous phenotype. To do this, patient collection remains
fundamental in genetic research and clinical analysis has to
include a detailed description of diet and lifestyle. To have
new insights about causal genes of nephrolithiasis, techno-
logical skills should be coupled with the ancient art of
evaluating patients with standardized and precise clinical
methods.
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